Immtech News (AMEX:IMM)
| Latest Immtech News Headlines | | Date | Time | Source | | | 03/12/2008 | 4:45PM | PRNUS | Immtech Announces Update on Business Operations
NEW YORK, March 12 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced today that Eric L. Sorkin, the Company's Chairman and Chief Executive Officer, and Cecilia Chan, Vice Chairman of Immtech, have volunteered to reduce their annual salary during fiscal year 2008.
Eric L. Sorkin, Immtech's... More...>> |
| 02/25/2008 | 9:43AM | PRNUS | Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuram
WOODCLIFF LAKE, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE:PRX) today announced that its development partner, Immtech Pharmaceuticals, Inc. (AMEX:IMM) has chosen to discontinue the development... More...>> |
| 02/22/2008 | 4:33PM | PRNUS | Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
NEW YORK, Feb. 22 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) today announced that the Company will focus on its new drug discovery programs targeting Hepatitis C, and drug-resistant bacterial and fungal infections, and will discontinue all development programs for pafuramidine maleate ("pafuramidine... More...>> |
| 02/19/2008 | 5:30PM | PRNUS | Immtech Investor Conference Call Scheduled for February 22, 2008
NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) will have an investor conference call on February 22, 2008, at 4.30PM (ET) to present an update on the Company. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside... More...>> |
| 02/13/2008 | 6:30AM | PRNUS | Immtech Appoints Blythe Weigh as Strategic Advisor
NEW YORK, Feb. 13 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (the "Company") (AMEX:IMM) is pleased to announce the appointment of leading corporate communications specialist Blythe Weigh Communications (Blythe Weigh) as strategic advisor to the Company (http://www.blytheweigh.com/).
Cecilia Chan, Vice... More...>> |
| 02/11/2008 | 4:04PM | PRNUS | Immtech Reports Fiscal Third Quarter 2008 Results
NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (the "Company") (AMEX:IMM) today announced results for its fiscal third quarter ended December 31, 2007.
For the three months ended December 31, 2007, revenues were $1,835,000, as compared to $546,000 for the three months ended December 31, 2006... More...>> |
| 02/06/2008 | 5:08PM | PRNUS | Immtech Investor Conference Call Scheduled for February 11, 2008
NEW YORK, Feb. 6 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) will have an investor conference call on Monday, February 11, 2008, at 4.30 PM (ET) to discuss its financial results for the quarter ended December 31, 2007 and to present an update on the Company's scientific and clinical progress... More...>> |
| 12/28/2007 | 11:44AM | PRNUS | Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
NEW YORK, Dec. 28 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) will hold an investor conference call on Thursday, January 3, 2008, at 1 PM (ET) to present an update on the Company's safety study for pafuramidine, the Company's oral drug candidate. Investors and interested parties in the U.S. are... More...>> |
| 12/26/2007 | 10:54AM | PRNUS | Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
NEW YORK, Dec. 26 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced today that it is working with clinical investigators at the South African site where a safety study is in progress for pafuramidine (DB289), an investigational therapy. In preliminary findings from the study, abnormal laboratory... More...>> |
| 12/04/2007 | 11:25PM | PRNUS | Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced today that the Company has granted an exclusive license to BioAlliance Pharma SA (Euronext Paris - ticker code BIO) to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Europe for the treatment of pneumocystis... More...>> |
| 12/03/2007 | 11:25AM | PRNUS | Immtech to Present at The Bank of Montreal Healthcare Conference
NEW YORK, Dec. 3 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced today that it will present at the Bank of Montreal (BMO) Capital Markets Focus on Healthcare Conference. On Tuesday, December 4, 2007 at 11:00am Eastern Time, Immtech is scheduled to present in the Biotechnology Room 4.04... More...>> |
| 11/29/2007 | 12:58PM | PRNUS | Dr. Jubo Liu Joins Immtech China as Development Liaison for Clinical Trials
NEW YORK, Nov. 29 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) is pleased to announce that Jubo Liu, Ph.D., has joined Immtech as Development Liaison for Clinical Trials in China. Dr. Liu will coordinate and manage Immtech's clinical development program in China, which currently includes the phase... More...>> |
| 11/29/2007 | 12:30PM | PRNUS | Immtech Announces Posting of Annual Shareholders Meeting Presentation
NEW YORK, Nov. 29 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced that the presentation to be made during the annual shareholders meeting will be posted on the Company's website, http://www.immtechpharma.com/, prior to the meeting.
About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals... More...>> |
| 11/08/2007 | 4:49PM | PRNUS | Immtech Reports Fiscal Second Quarter 2008 Results
NEW YORK, Nov. 8 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) today announced results for its fiscal second quarter ended September 30, 2007.
For the three months ended September 30, 2007, revenues were $1,030,000, as compared to $491,000 for the three months ended September 30, 2006. The increase... More...>> |
| 11/08/2007 | 9:15AM | PRNUS | Immtech Investor Conference Call Scheduled for November 9 at 3 PM
NEW YORK, Nov. 8 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) will hold a conference call on Friday, November 9, at 3.00 p.m. (ET) to present an update on the Company's progress. The User Access Code is # 23641366. Investors and interested parties in the U.S. are invited to join the call by dialing... More...>> |
| 11/05/2007 | 2:54PM | PRNUS | Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
NEW YORK, Nov. 5 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) today announced that it has received $5.1 million from a scientific consortium led by the University of North Carolina at Chapel Hill (UNC), which received funds from The Bill & Melinda Gates Foundation (the "Gates Foundation"), to develop... More...>> |
| 11/05/2007 | 2:41PM | PRNUS | Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
NEW YORK, Nov. 5 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced today that it will present at the Acumen BioFin(TM) Rodman & Renshaw 9th Annual Healthcare Conference.
On Tuesday, November 6 at 2:40 p.m. Eastern Time, Immtech is scheduled to present in the Hubbard Room, 5th floor, at the... More...>> |
| 11/02/2007 | 9:08AM | PRNUS | Immtech Completes Malaria Prevention Trial
Results support focus on preventing blood-stage disease
NEW YORK, Nov. 2 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced today that it has completed its first malaria prevention (or "malaria challenge") trial of pafuramidine, Immtech's oral drug candidate. The exploratory study was designed... More...>> |
| 10/04/2007 | 8:59AM | PRNUS | Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Data Safety Monitoring Board Recommends Continuing Study
NEW YORK, Oct. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX:IMM) announced today the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring... More...>> |
| 09/27/2007 | 8:55AM | PRNUS | Chinese SFDA Grants Immtech Fast Track Status
NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Immtech) (AMEX:IMM) announced today that the State Food and Drug Administration of the People's Republic of China (SFDA) has granted Immtech's application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the Company's... More...>> |
|
|
|